Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20377
Title: | 惡性膽道阻塞接受內視鏡逆行性和經皮穿肝順行性金屬支架置放的併發症比較 Comparison of adverse effects after metallic stenting for malignant biliary obstruction between endoscopic retrograde and percutaneous transhepatic antegrade routes |
Authors: | Min-Horn Tsai 蔡明宏 |
Advisor: | 王秀伯,鄭祖耀 |
Keyword: | 惡性膽道阻塞,膽道金屬支架,內視鏡逆行性膽道支架置放術,經皮穿肝膽管引流,併發症, malignant biliary obstruction,biliary metal stent,endoscopic retrograde biliary drainage,percutaneous transhepatic cholangial drainage,complication, |
Publication Year : | 2017 |
Degree: | 碩士 |
Abstract: | 惡性腫瘤會造成許多併發症,包括膽道阻塞併發黃疸。阻塞性黃疸的相關症狀包刮皮膚癢、噁心、食慾低落、發燒、傷口癒合延遲、生活品質下降等。惡性膽道阻塞通常在癌症的晚期或末期發生。緩解惡性膽道阻塞除了改善病人的生活品質,還能降低醫療支出。目前可以經由內視鏡逆行性或經皮順行性置放膽道金屬支架進行膽道引流,不只成功率高,也能維持較久的時間。但目前僅有少數的研究比較這兩種不同的方式所造成的副作用。因此,此研究是針對這兩種方式所引發的相關併發症,包括感染、支架位移、支架阻塞、胰臟炎、膽囊炎等,進行比較及探討。 Malignant tumors may cause a variety of complications including malignant biliary obstruction related jaundice. The symptoms of obstructive jaundice such as pruritus, nausea, loss of appetite, fever, delayed wound healing, decrease patient’s quality of life significantly. Usually malignant biliary obstruction will develop in the advanced or terminal cancer stage. Relieving malignant biliary obstruction not only improves patient’s quality of life but also decreases medical cost. Currently, both endoscopic retrograde and percutaneous antegrade biliary drainage could achieve high successful rates and maintain longer duration. But few studies compare the adverse effect of the two methods. The aim of this study is to compare the adverse effect of the two methods, including infection, stent migration, stent occlusion, pancreatitis, cholecystitis, etc. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20377 |
DOI: | 10.6342/NTU201704134 |
Fulltext Rights: | 未授權 |
Appears in Collections: | 臨床醫學研究所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-106-1.pdf Restricted Access | 474.14 kB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.